| Title |
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
|
|---|---|
| Published in |
Biologics: Targets & Therapy, May 2013
|
| DOI | 10.2147/btt.s30416 |
| Pubmed ID | |
| Authors |
Tamsin Gledhill, Keith Bodger |
| Abstract |
Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 11% |
| Belgium | 1 | 11% |
| Unknown | 7 | 78% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 63 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 14 | 22% |
| Researcher | 12 | 19% |
| Student > Master | 7 | 11% |
| Student > Bachelor | 7 | 11% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 12 | 19% |
| Unknown | 7 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 42% |
| Agricultural and Biological Sciences | 8 | 13% |
| Immunology and Microbiology | 3 | 5% |
| Economics, Econometrics and Finance | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Other | 13 | 20% |
| Unknown | 7 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2013.
All research outputs
#6,997,226
of 25,374,647 outputs
Outputs from Biologics: Targets & Therapy
#88
of 284 outputs
Outputs of similar age
#55,568
of 204,331 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 7 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,331 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.